Determinants of maximal dose titration of sacubitril/valsartan in clinical practice.

Pieter MartensLina VerluytenHeleen Van de BroekFrauke SomersJeroen DauwMatthias DupontWilfried Mullens

Published in: Acta cardiologica (2019)

Uptitration to the maximal dose of sacubitril/valsartan is possible in up to 32% of real-world HFrEF-patients in our cohort, which relates to both patient characteristics' as well as heart failure care-related factors.

Keyphrases

ejection fraction
heart failure
end stage renal disease
clinical practice
healthcare
newly diagnosed
heart rate
resistance training
chronic kidney disease
palliative care
prognostic factors
case report
left ventricular
atrial fibrillation
blood pressure
acute heart failure
high intensity
affordable care act